Taipei City | Date: January 14, 2025
YC Biotech Co., Ltd. is actively expanding its clinical research footprint in the field of aesthetic medicine. The company recently announced the launch of an innovative clinical research project at Shuang Ho Hospital, part of the Taipei Medical University Healthcare System. This study will focus on evaluating the safety and efficacy of injectable dermal fillers for facial applications, with the trial set to begin in January 2025 and run for one year.
Through systematic clinical data collection and analysis, the study aims to comprehensively assess the effects of injectable fillers across different facial regions. In addition to evaluating safety parameters, the research will establish a robust efficacy assessment framework.
As the aesthetic medicine market continues its rapid expansion, establishing reliable clinical evidence has become increasingly critical. This research initiative will leverage advanced imaging analysis technology and standardized evaluation tools to provide valuable clinical insights for both medical professionals and consumers. The key objectives of the study include developing standardized safety assessment criteria for dermal filler applications, collecting long-term follow-up data from various treatment sites, and analyzing clinical outcome variations across different injection techniques.
Upon regulatory approval, YC Biotech will deploy its expert team to execute this clinical study. By conducting rigorous data collection and analysis, the company aims to reinforce the scientific foundation of Taiwan’s aesthetic medicine industry while enhancing consumer confidence in medical aesthetic treatments. This initiative reflects YC Biotech’s commitment to continuous innovation in clinical research, as it continues to deepen its expertise across various medical research fields.